- Home
- UFI vs KYTX Comparison
UFI vs KYTX Comparison
Compare UFI & KYTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UFI
- KYTX
- Stock Information
- Founded
- UFI 1969
- KYTX 2018
- Country
- UFI United States
- KYTX United States
- Employees
- UFI N/A
- KYTX N/A
- Industry
- UFI Textiles
- KYTX
- Sector
- UFI Consumer Discretionary
- KYTX
- Exchange
- UFI Nasdaq
- KYTX NYSE
- Market Cap
- UFI 91.3M
- KYTX 92.1M
- IPO Year
- UFI N/A
- KYTX 2024
- Fundamental
- Price
- UFI $4.87
- KYTX $3.07
- Analyst Decision
- UFI
- KYTX Strong Buy
- Analyst Count
- UFI 0
- KYTX 5
- Target Price
- UFI N/A
- KYTX $19.00
- AVG Volume (30 Days)
- UFI 38.8K
- KYTX 415.4K
- Earning Date
- UFI 04-30-2025
- KYTX 08-11-2025
- Dividend Yield
- UFI N/A
- KYTX N/A
- EPS Growth
- UFI N/A
- KYTX N/A
- EPS
- UFI N/A
- KYTX N/A
- Revenue
- UFI $590,261,000.00
- KYTX N/A
- Revenue This Year
- UFI $1.08
- KYTX N/A
- Revenue Next Year
- UFI $9.96
- KYTX N/A
- P/E Ratio
- UFI N/A
- KYTX N/A
- Revenue Growth
- UFI 2.51
- KYTX N/A
- 52 Week Low
- UFI $4.25
- KYTX $1.78
- 52 Week High
- UFI $7.91
- KYTX $11.40
- Technical
- Relative Strength Index (RSI)
- UFI 47.76
- KYTX 55.92
- Support Level
- UFI $4.83
- KYTX $2.86
- Resistance Level
- UFI $5.12
- KYTX $2.82
- Average True Range (ATR)
- UFI 0.22
- KYTX 0.31
- MACD
- UFI -0.01
- KYTX -0.03
- Stochastic Oscillator
- UFI 27.59
- KYTX 40.94
About UFI Unifi Inc. New
Unifi Inc is a multi-national company. It manufactures and sells synthetic and recycled products made from polyester and nylon predominantly to other yarn manufacturers and knitters and weavers that produce fabric for apparel, hosiery, home furnishings, automotive, industrial, and other end-use markets. Polyester yarns include partially oriented yarn (POY), textured, solution and package dyed, twisted, beamed, and draw wound yarns, and each is available in virgin or recycled varieties. UNIFI offers specialized yarns, premium value-added (PVA) yarns, and commodity yarns. The company's reportable segments are; the Americas, Brazil, and Asia. Its maximum revenue is derived from the Americas.
About KYTX KYVERNA THERAPEUTICS INC
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.